Valbenazine (Ingrezza®) and VMAT2

Valbenazine (Ingrezza®) is a selective inhibitor of vesicular monoamine transporter 2 (VMAT 2). In April, 2017, it was approved by the FDA for the treatment of adults with tardive dyskinesia. It is the first medication ever to be FDA-approved for the treatment of tardive dyskinesia. However, it is not the first or only VMAT 2…

This content is for Monthly Membership and Yearly Membership members only.Log InRegister